Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Nicotinic agonists and psychosis.

J K Simosky¹, K E Stevens, R Freedman

¹Department of Pharmacology, University of Colorado Health Sciences Center, Denver, CO 80262, USA. johanna.simosky@uchsc.edu

Current Drug Targets. CNS and Neurological Disorders

|May 29, 2003

Summary

Schizophrenia patients exhibit auditory gating deficits, which smoking temporarily improves. Novel alpha7 nicotinic receptor agonists show promise for treating this deficit and potentially schizophrenia itself.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Species-specific thermal classification schemes can improve climate related marine resource decisions.

PloS one·2021

Same author

Publishing what's important.

Acta psychiatrica Scandinavica·2015

Same author

Translational utility of rodent hippocampal auditory gating in schizophrenia research: a review and evaluation.

Translational psychiatry·2015

Same author

Reduced CHRNA7 expression in C3H mice is associated with increases in hippocampal parvalbumin and glutamate decarboxylase-67 (GAD67) as well as altered levels of GABA(A) receptor subunits.

Neuroscience·2014

Same author

A compact high-performance low-field NMR apparatus for measurements on fluids at very high pressures and temperatures.

The Review of scientific instruments·2014

Same author

Long-term beneficial effects of adrenal medullary autografts supported by nerve growth factor in Parkinson's disease.

European journal of neurology·2013

Area of Science:

Neuroscience
Psychiatry
Pharmacology

Background:

Schizophrenia is characterized by impaired auditory gating, a deficit linked to symptom severity.
This auditory gating deficit is unresponsive to typical antipsychotics but improves with clozapine and transiently with nicotine.
Nicotine's temporary normalization of auditory gating in schizophrenia patients suggests a self-medication hypothesis.

Purpose of the Study:

To explore the role of alpha7 nicotinic receptors in schizophrenia's auditory gating deficit.
To evaluate novel therapeutic strategies targeting alpha7 nicotinic receptors for schizophrenia treatment.

Main Methods:

Review of existing literature on auditory gating, schizophrenia, and nicotinic receptor modulation.
Discussion of preclinical data for alpha7-selective agonists like DMXB-A.
Consideration of clozapine's efficacy and allosteric modulators as therapeutic avenues.

Main Results:

Auditory gating deficits in schizophrenia are modulated by the alpha7 nicotinic receptor subtype.
The alpha7-selective agonist DMXB-A normalized auditory gating in animal models.
Clozapine demonstrates efficacy in normalizing auditory gating deficits.

Conclusions:

Selective alpha7 nicotinic receptor agonists represent a potential novel pharmacotherapy for schizophrenia.
Further clinical trials are needed to establish the efficacy of DMXB-A in schizophrenia patients.
Targeting alpha7 nicotinic receptors offers a promising therapeutic direction for addressing auditory gating deficits in schizophrenia.

Related Experiment Videos